Opinion|Videos|September 6, 2024
Need for early intervention in corneal conditions
Medical experts discuss the need for early intervention in corneal conditions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Why is early detection crucial in the management of corneal conditions, and what are the potential complications of delayed diagnosis?
Advertisement
Related to this article
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for optometrists managing near vision loss.
Enspryng is the first subcutaneous, at-home treatment option for TED and the first interleukin (IL)-6 receptor inhibitor approved in the indication.
Susan Gromacki, OD, MS, FAAO, FSLS, details one of her AAOpt 2026 sessions, titled "Advances in Contact Lens Care for the New Contact Lens Technologies."
Three researchers share the prize for discovering channelrhodopsin, a light-sensitive protein now being tested to restore vision in retinal disease.
Presenters from AAOpt26's research symposium share their findings, applications for optometric practice, and goals for future study.
FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Missed AAOpt 2026? Here are the highlights by specialty
3
AAOpt 2026: Keeping up with contact lens care as technology advances
4
FDA approves subcutaneous Enspryng for TED
5